pTERT突变状态与接受一线免疫治疗的IV期黑色素瘤患者生存相关
该研究分析774例已知pTERT状态的黑色素瘤患者,其中476例(61.5%)存在TERT启动子突变;在374例接受一线免疫检查点抑制剂或靶向治疗的IV期患者中,pTERT阳性者接受抗CTLA4/抗PD1联合治疗的中位无进展生存期14.8个月、中位总生存期105.2个月,优于pTERT阴性者的5.5个月和14.7个月。
要点
- pTERT突变见于61.5%(476/774)的黑色素瘤患者。
- IV期pTERT阳性者接受抗CTLA4/抗PD1联合治疗的中位PFS为14.8个月,中位OS为105.2个月。
- pTERT阴性者接受同方案的中位PFS为5.5个月,中位OS为14.7个月。
核心结论
- 研究提示黑色素瘤存在pTERT突变可能有利于一线免疫检查点抑制剂后的PFS和OS,抗CTLA4/抗PD1联合治疗改善最明显。
- 作者认为若在更大规模前瞻性研究中验证,pTERT突变状态可能成为IV期黑色素瘤患者有价值的预后标志物。
研究设计与样本
- 研究评估2013年至2021年覆盖29个基因的测序数据及pTERT状态,分析774例已知pTERT状态且有临床数据的黑色素瘤患者。
- 对374例接受一线免疫检查点抑制剂(抗CTLA4/抗PD1联合治疗或抗PD1单药)或靶向治疗的AJCC IV期患者,采用Cox单因素/多因素分析和Kaplan-Meier曲线评估PFS和OS。
主要发现
- 队列包括573例皮肤型、69例黏膜型、37例肢端型和95例原发灶不明黑色素瘤,从首次诊断到患者死亡或删失的中位观察时间为38.5个月。
- 476例黑色素瘤(61.5%)检出TERT启动子突变。
- 374例IV期接受一线系统治疗(ICI或TT)患者中,pTERT阳性者PFS和OS提示延长。
- 接受抗CTLA4/抗PD1治疗的pTERT阳性者中位PFS为14.8个月(95%CI:7.1-40.3),中位OS为105.2个月(95%CI:27.6-未达到);pTERT阴性者中位PFS为5.5个月(95%CI:2.7-10.0),中位OS为14.7个月(95%CI:11.7-24.1)。
临床怎么用
- 作者认为pTERT突变状态若在更大规模前瞻性研究中验证,可能成为IV期黑色素瘤患者有价值的预后标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: TERT promoter mutations are the most prevalent mutations in melanoma. In this study, we investigated clinical characteristics and survival after first line therapies in a cohort of melanoma patients with known TERT promoter (pTERT) mutation status. METHODS: Sequencing data from 2013 to 2021 covering 29 genes and the pTERT status was assessed and 774 melanomas patients with known pTERT status and clinical data were analyzed. Progression free survival (PFS) and overall survival (OS) of 374 melanoma patients in AJCC-stage IV who received first-line immune checkpoint inhibitors (ICI, anti-CTLA4 /anti-PD1 combination therapy or anti-PD1 monotherapy) or targeted therapy (TT) were assessed applying Cox uni-/ multivariable analyses and Kaplan-Meier curves. RESULTS: The cohort included 573 cutaneous, 69 mucosal, 37 acral and 95 MUP (melanomas of unknown primary) melanoma patients with a median observational time from first diagnosis to patient death or censoring of 38.5 months. TERT promoter mutations were identified in 476 melanomas (61.5 %). Survival analysis of 374 patients with stage IV disease undergoing first-line systemic therapy (ICI or TT) suggested prolonged PFS and OS for patients with pTERT mutation positive tumors (pTERT(+)). Particularly, pTERT(+) patients receiving anti-CTLA4/anti-PD1 therapy showed mPFS of 14.8 months (95 % CI: 7.1-40.3) and mOS of 105.2 months (95 % CI: 27.6-not reached) compared to pTERT(-) patients with mPFS of 5.5 months (95 % CI: 2.7-10.0) and mOS of 14.7 months (95 % CI: 11.7-24.1). CONCLUSIONS: Our findings suggest that presence of a pTERT mutation in melanomas might favor PFS and OS after first line ICI with the greatest improvement after receiving anti-CTLA4 / anti-PD1. If validated in larger prospective studies, pTERT mutation status may be a valuable prognostic marker for stage IV melanoma patients.
引用
- Jansen P, Galetzka W, Thielmann CM, et al. pTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapy. Eur J Cancer. 2025. PMID: 40056560. doi:10.1016/j.ejca.2025.115337
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。